The phase III clinical trial for advanced breast cancer concluded that combination of exemestane and entinostat did not improve survival in AI-resistant advanced HR-positive, HER2-negative breast cancer (clinicaltrials.gov). Here, ERBB2 is linked to breast carcinoma.